Atyr Pharma Provides Update On Timing Of Regulatory Response For Planned Phase 3 Study Of Efzofitimod In Pulmonary Sarcoidosis

ATYR•2026-09-01

Regulatory response timing update

aTyr Pharma Inc. said it expects FDA response by mid-September 2026 for its planned Phase 3 study of efzofitimod in pulmonary sarcoidosis.

Atyr Pharma Provides Update On Timing Of Regulatory Response For Planned Phase 3 Study Of Efzofitimod In Pulmonary Sarcoidosis

Regulatory response timing update

Related News

California Water Service director Lester A. Snow disposes of 500 common shares worth $25,105

Ero Copper announces 2026 Capital Markets Day meeting

Calumet - MRL And DOE Enter First Amendment To Loan Guarantee Agreement On August 28, 2026 - SEC Filing

Guggenheim Investments Announces September 2026 Closed-End Fund Distributions

IIPR Director Bruce Alan Ives acquires 528 Innovative Industrial Properties common shares for $29,937.6